DUBLIN--(BUSINESS WIRE)--The "Drug Overview: Eliquis" report has been added to ResearchAndMarkets.com's offering. Eliquis (Apixaban; Bristol-Myers Squibb/Pfizer) is an orally available factor Xa ...

FDA Accepts ELIQUIS® (apixaban) New Drug Application for Review for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation PRINCETON, N.J. & NEW YORK--(BUSINESS ...

SILVER SPRING, Md., Dec. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration has approved two applications for the first generics of Eliquis (apixaban) tablets to reduce the risk of stroke ...

Eliquis had a market value of $14 billion during the 12 months ended May 2021, according to industry data. The Food and Drug Administration has cleared Breckenridge’s apixaban tablets. The medication ...

For patients with HIV and atrial fibrillation, this study found that apixaban was associated with less bleeding when compared with warfarin and rivaroxaban. Data remain inconclusive regarding ...

Bristol-Myers Squibb Laura Hortas, 609-252-4587, John Elicker, 609-252-4611, orPfizer Inc.MacKay Jimeson, 212-733-2324, Suzanne Harnett, 212-733-8009, (NYSE: BMY) and (NYSE: PFE) today announced that ...

TAIPEI, Feb. 17, 2025 /PRNewswire/ -- TAHO Pharmaceuticals announces positive preliminary results from the pivotal study of TAH3311, the world's first Apixaban oral dissolving film (ODF). The study ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — In patients with atrial fibrillation requiring stroke prevention, the novel factor XIa inhibitor ...

PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has extended the action ...

TAIPEI, Oct. 1, 2025 /CNW/ -- TAHO Pharmaceuticals Ltd. ("TAHO Pharma") today announced the submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for TAH3311, the ...